Weight loss results In a 2022 review of 22 studies that included more than 17,000 people with or without type 2 diabetes treated with semaglutide or liraglutide: More than 50% of participants treated with either semaglutide or liraglutide lost 5% or more of their starting weight after an average of 39 weeks on the medicine About 17% of participants lost 10% or more of their body weight in the same period A phase 3 clinical trial studied treatment with tirzepatide in people with obesity and found that it produced substantial and sustained weight loss at various dose strengths
However, there was no significant improvement in fibrosis stage by semaglutide therapy
If you are taking insulin or sulphonylureas alongside GLP-1 medications, these doses may need adjustment when stopping GLP-1 therapy
Employers generally don't pay the list price for employee coverage, but even after various discounts, plan sponsors may pay a net price of around $569 to $664 a month per employee, according to estimates by the Institute for Clinical and Economic Review, making for a hefty bill
The more options people have, the better, says Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine
doi: 10.1002/cpt.1556